Multi-target designs can reduce tumor escape risk by targeting MSLN and co-expressed tumor antigens; combining strategies such as oncolytic viruses or cancer vaccines, or low-dose immune checkpoint inhibitors to modulate the tumor microenvironment, can further enhance therapeutic efficacy. This evidence concerns the gene MSLN and cancer.